MarketCap
Facebook
X
TelegramQuarterly report 2026-Q1
added 05-13-2026
Inovio Pharmaceuticals Cash and Cash Equivalents 2011-2026 | INO
Annual Cash and Cash Equivalents Inovio Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 44.3 M | 65.8 M | 14.3 M | 46.3 M | 71.1 M | 251 M | 22.2 M | 23.7 M | 23.8 M | 19.1 M | 57.6 M | 40.5 M | 33.7 M | 5.65 M | 17.4 M | 20 M | 30.3 M | 14.1 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 251 M | 5.65 M | 44.5 M |
Quarterly Cash and Cash Equivalents Inovio Pharmaceuticals
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26.3 M | 36.6 M | 24.4 M | 39.9 M | 65.8 M | 21.7 M | 34.4 M | 19.6 M | 14.3 M | 18.8 M | 52.7 M | 28.2 M | 46.3 M | 22 M | 41.1 M | 59 M | 71.1 M | 67.9 M | 58.9 M | 83.6 M | 251 M | 251 M | 251 M | 251 M | 22.2 M | 22.2 M | 22.2 M | 22.2 M | 23.7 M | 23.7 M | 23.7 M | 23.7 M | 23.8 M | 23.8 M | 23.8 M | 23.8 M | 19.1 M | 19.1 M | 19.1 M | 19.1 M | 57.6 M | 57.6 M | 57.6 M | 57.6 M | 40.5 M | 40.5 M | 40.5 M | 40.5 M | 33.7 M | 33.7 M | 33.7 M | 33.7 M | 5.65 M | 5.65 M | 5.65 M | 5.65 M | 17.4 M | 17.4 M | 17.4 M | 17.4 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 251 M | 5.65 M | 46.8 M |
Cash and Cash Equivalents of other stocks in the Biotechnology industry
| Issuer | Cash and Cash Equivalents | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
FSD Pharma
HUGE
|
1.91 M | - | 5743.5 % | $ 69.7 M |  Canada |
 |
MorphoSys AG
MOR
|
158 M | - | 2.43 % | $ 254 M |  Germany |
 |
Happiness Biotech Group Limited
HAPP
|
261 K | - | 1.35 % | $ 17.8 M |  China |
 |
AgeX Therapeutics
AGE
|
3.06 M | - | -10.17 % | $ 12.2 K |  USA |
 |
Coherus BioSciences
CHRS
|
88.9 M | $ 1.72 | 4.57 % | $ 201 M | USA |
 |
I-Mab
IMAB
|
4.76 B | - | - | $ 866 M | China |
 |
Celldex Therapeutics
CLDX
|
28.9 M | $ 31.69 | 2.72 % | $ 2.1 B | USA |
 |
Biophytis SA
BPTS
|
5.57 M | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
81.8 M | - | 2.54 % | $ 160 B | France |
 |
BioNTech SE
BNTX
|
7.68 B | $ 93.95 | 1.84 % | $ 22.7 B | Germany |
 |
AstraZeneca PLC
AZN
|
5.71 B | - | - | $ 96.9 B |  Britain |
 |
CRISPR Therapeutics AG
CRSP
|
348 M | $ 53.5 | 3.69 % | $ 4.81 B |  Schweiz |
 |
Athira Pharma
ATHA
|
69.3 M | - | - | $ 269 M | USA |
 |
BiondVax Pharmaceuticals Ltd.
BVXV
|
54 M | - | 0.74 % | $ 768 M |  Israel |
 |
Compugen Ltd.
CGEN
|
90.6 M | $ 2.66 | 0.38 % | $ 249 M | Israel |
 |
Abcam plc
ABCM
|
89 M | - | - | $ 4.9 B | Britain |
 |
Galera Therapeutics
GRTX
|
6.38 M | - | -32.59 % | $ 7.61 M | USA |
 |
Midatech Pharma plc
MTP
|
8.53 M | - | -18.52 % | $ 27.3 M | Britain |
|
Enlivex Therapeutics Ltd.
ENLV
|
1.89 M | $ 0.77 | 12.35 % | $ 35.2 M | Israel |
 |
Esperion Therapeutics
ESPR
|
168 M | $ 3.13 | 0.16 % | $ 651 M | USA |
 |
Eton Pharmaceuticals
ETON
|
25.9 M | $ 32.21 | 2.94 % | $ 867 M | USA |
 |
Affimed N.V.
AFMD
|
38.5 M | - | -34.95 % | $ 21.5 M | Germany |
|
Forte Biosciences
FBRX
|
77 M | $ 22.24 | 1.37 % | $ 288 M | USA |
 |
Checkmate Pharmaceuticals
CMPI
|
50.7 M | - | - | $ 231 M | USA |
 |
Celyad Oncology SA
CYAD
|
12.4 M | - | - | $ 12.5 M |  Belgium |
 |
Berkeley Lights
BLI
|
86.5 M | - | -7.31 % | $ 87 M | USA |
 |
Galectin Therapeutics
GALT
|
17.7 M | $ 2.76 | -1.25 % | $ 176 M | USA |
 |
Generation Bio Co.
GBIO
|
76.3 M | - | - | $ 344 M | USA |
 |
IMV
IMV
|
21.2 M | - | - | $ 13.1 M | Canada |
 |
Akero Therapeutics
AKRO
|
340 M | - | - | $ 3.67 B | USA |
 |
Akouos
AKUS
|
122 M | - | 0.23 % | $ 488 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
2.41 M | - | - | $ 7.46 M | Israel |
 |
Grifols, S.A.
GRFS
|
980 M | $ 8.1 | 1.12 % | $ 5.51 B |  Spain |
 |
Hutchison China MediTech Limited
HCM
|
71.3 M | $ 11.87 | 1.06 % | $ 10.2 B | China |
 |
Cyclacel Pharmaceuticals
CYCCP
|
3.5 M | - | -4.36 % | $ 27 M | USA |
 |
Freeline Therapeutics Holdings plc
FRLN
|
47.3 M | - | - | $ 384 M | Britain |
 |
Heron Therapeutics
HRTX
|
28.6 M | $ 0.91 | 2.56 % | $ 152 M | USA |
 |
Gracell Biotechnologies
GRCL
|
1.45 B | - | - | $ 3.37 B | China |
 |
Anika Therapeutics
ANIK
|
57.5 M | $ 14.86 | -0.2 % | $ 213 M | USA |
 |
Advaxis
ADXS
|
4.88 M | - | -9.65 % | $ 45.9 M | USA |
 |
Aeterna Zentaris
AEZS
|
7.31 M | - | 5.93 % | $ 314 M | Canada |
 |
InflaRx N.V.
IFRX
|
16 M | $ 2.62 | -4.45 % | $ 176 M | Germany |
 |
Aeglea BioTherapeutics
AGLE
|
85.7 M | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
811 M | - | - | $ 867 M | Germany |
 |
Applied Genetic Technologies Corporation
AGTC
|
46.4 M | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
34 M | - | 1.93 % | $ 17.4 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
5.53 M | $ 3.33 | -3.2 % | $ 5.48 M | Israel |